Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



The Latest Skirmish in the Patent Wars

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

A long time ago in a galaxy far, far away, there were… Patent Wars. Actually, the time is now and the galaxy is our own, but the patent wars are real -- and the battles can be intense.

The latest exchange of fire resulted in a small victory for Alnylam Pharmaceuticals (Nasdaq: ALNY  ) and Isis Pharmaceuticals (Nasdaq: ISIS  ) . The U.S. District Court in Massachusetts denied Tekmira's bid to have some claims dismissed and to disqualify Alnylam's legal representatives.

Battle lines
This particular battle is being waged because Alnylam alleges that Tekmira infringed on several patents, including one owned by Alnylam's business partner, Isis. The patents relate to technology involving lipid nanoparticle-formulated small interfering RNA molecules. Just reading about LNP and siRNA gets your blood boiling too, doesn't it?

All kidding aside, this technology is a big deal. Advances in RNA interference won the Nobel Prize for Physiology or Medicine in 2006. Small interfering RNA can be used to silence specific genes that produce proteins that ultimately cause various diseases.

Tekmira is one of the smaller entities to which Alnylam granted licenses for development of RNAi therapeutics. Alnylam partners with several large companies in its development efforts, including AstraZeneca (NYSE: AZN  ) and Monsanto (NYSE: MON  ) . The company ended an earlier alliance with Merck (NYSE: MRK  ) in 2007.

Worth the fight
ALN-TTR is Alnylam's product farthest along in the pipeline. This RNAi therapeutic targets treatment of amyloidosis caused by the transthyretin protein, commonly referred to as ATTR. Jaffray analyst Edward Tenthoff predicts that the drug could ultimately reach blockbuster status with global sales of $2 billion. That is an amount definitely worth fighting for.

The recent court ruling amounts to little at this point. Tekmira's attempt to have claims dismissed and attorneys disqualified is akin to firing shots over the enemy's heads. You can bet, though, that this battle will keep going for a while.

Investors might want to consider joining in the melee on their own terms. Alnylam shares have traded in the range of $17 to $21 per share since the company reported positive results in July from an early-stage trial. If the stock pulls back to around the $18 per share mark, it could be a good time to pull the trigger.   

More fireworks
If you're looking for more positive investing fireworks, check out The Motley Fool's special report "These Stocks Could Skyrocket After the 2012 Presidential Election". It's totally free, so get your copy now by clicking here!

Fool contributor Keith Speights owns no shares in the stocks mentioned above. Motley Fool newsletter services have recommended creating a synthetic covered calls position in Monsanto. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2032785, ~/Articles/ArticleHandler.aspx, 10/25/2016 7:20:43 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,169.27 -53.76 -0.30%
S&P 500 2,143.16 -8.17 -0.38%
NASD 5,283.40 -26.43 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 4:00 PM
ALNY $36.67 Down -0.53 -1.42%
Alnylam Pharmaceut… CAPS Rating: ***
AZN $29.79 Down -0.29 -0.96%
AstraZeneca CAPS Rating: ****
IONS $27.16 Down -0.49 -1.77%
Ionis Pharmaceutic… CAPS Rating: *****
MON $101.40 Down -0.60 -0.59%
Monsanto CAPS Rating: ***
MRK $61.95 Up +1.20 +1.98%
Merck and Co. CAPS Rating: ****